SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001851734-23-000021
Filing Date
2023-01-25
Accepted
2023-01-24 17:32:54
Documents
15
Period of Report
2023-01-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230124_8k.htm   iXBRL 8-K 26867
2 EXHIBIT 99.1 ex_467360.htm EX-99.1 12878
7 vtgn.jpg GRAPHIC 4171
  Complete submission text file 0001851734-23-000021.txt   182867

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230124.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230124_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230124_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230124_pre.xml EX-101.PRE 11688
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230124_8k_htm.xml XML 2594
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 23549169
SIC: 2834 Pharmaceutical Preparations